Personalis, Inc..
PSNL.US | Research and experimental development on natural sciences and engineering
Personalis, Inc. is a precision oncology company transforming the development of next-generation cancer therapies. The company develops and commercializes comprehensive genomic profiling solutions for cancer, enabling researchers and clinicians to personalize cancer treatments. Their ImmunoID NeXT P...Show More
Better Health for All
-30
Personalis, Inc. develops advanced cancer genomic tests and services, including NeXT Personal, ImmunoID NeXT, and NeXT Dx, which are used for early detection of residual or recurrent cancer, therapy monitoring, and therapy selection.
1
These products deliver revolutionary health benefits, with studies showing 100% detection of resectable Stage I-IV colorectal cancer relapses ahead of imaging, 100% of distant metastatic recurrences detected prior to imaging, and 100% five-year overall survival for ctDNA-negative lung adenocarcinoma patients.
2
The company's revenue is entirely derived from these diagnostic products, which do not have established negative health outcomes. The company's products are diagnostic tools and do not have direct safety implications for physical or mental health. The company faces challenges in obtaining reimbursement for its tests from Medicare and private insurance companies, and estimates approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare.
3
The company has a partnership with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) and is working with cancer centers to build clinical evidence.
4
The company's 10-K filing includes a detailed "Risk Factors" section outlining various operational, strategic, business, regulatory, legal, cybersecurity, intellectual property, financial, and market risks.
5
Personalis states a commitment to diversity and inclusion, including broader outreach and sourcing for candidates for new roles, as well as education and a visible commitment to diversity and inclusion internally.
6
The company offers competitive total rewards programs, ongoing training and development, and a commitment to the safety and health of its employees.
7
The company's tests are primarily for detecting existing cancer, with a limited focus on preventative health.
8
Personalis is subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security, with potential fines up to $250,000 per violation for non-compliance with HIPAA and HITECH.
9
Clinical trials for NeXT Personal complied with ethical regulations, were approved by an independent research ethics committee, and obtained informed consent from all patients.
10
However, the company faces potential enforcement action if the FDA determines its tests are subject to regulation as medical devices.
11
Fair Money & Economic Opportunity
0
No evidence available to assess Personalis, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
Employee reviews on Glassdoor indicate an overall employee rating of 3.5 out of 5, which is in line with the average for the Pharmaceutical & Biotechnology industry.
1
This rating corresponds to approximately 70% engagement, suggesting a healthy workplace culture. No specific quantitative data is available for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Personalis, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete data points were found in the provided article to assess Personalis, Inc. against any of the 'Honest & Fair Business' KPIs.
1
This includes regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy, complaint resolution times, board conflict of interest percentages, anti-corruption policies, or third-party verification of ethical claims.
2
Kind to Animals
0
No specific, concrete data points were found in the provided articles for Personalis, Inc. (PSNL.US) regarding any of the 'Kind to Animals' KPIs. The articles either discuss general industry trends and regulations without company-specific information or explicitly state that no data is available for PSNL.US.
1
No War, No Weapons
0
No evidence available to assess Personalis, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Personalis, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific data points were found in the provided article to assess Personalis, Inc. against the 'Respect for Cultures & Communities' KPIs.
1
The article explicitly states that it does not contain relevant data for the specified metrics.
2
Safe & Smart Tech
0
No evidence available to assess Personalis, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found across the provided articles to assess Personalis, Inc. against the defined KPIs for Zero Waste & Sustainable Products. While Article 1 mentions the company has "incorporated environmentally sustainable practices into certain of our facilities and operations,"
1
this statement lacks the quantitative detail (e.g., specific number of initiatives, waste diversion rates, percentages of sustainable packaging, or reduction targets) required by the rubric's KPIs. Article 3 explicitly states that it "does not provide specific data points for PSNL's waste diversion, product recyclability, packaging sustainability, or other requested metrics."
2
Therefore, all KPIs must be omitted due to a lack of measurable evidence.